Stockscreener 앱 받기
2.50
6.72%
-0.18
시간 외 거래:
1.76
-0.74
-29.60%
전일 마감가:
$2.68
열려 있는:
$2.49
하루 거래량:
64,277
Relative Volume:
0.85
시가총액:
$11.33M
수익:
$468.00K
순이익/손실:
$-10.34M
주가수익비율:
-0.3546
EPS:
-7.05
순현금흐름:
$-8.94M
1주 성능:
+3.31%
1개월 성능:
+24.38%
6개월 성능:
+2.88%
1년 성능:
-56.13%
1일 변동 폭
$2.41
$2.5905
1주일 범위
$2.41
$3.20
52주 변동 폭
$1.625
$6.15
Biocardia Inc Stock (BCDA) Company Profile
명칭
Biocardia Inc
전화
650-226-0123
주소
320 SOQUEL WAY, SUNNYVALE, CA
BCDA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.26 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1555 | 349.69M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
MOBBW
Mobilicom Limited Warrants
|
0.2267 | 318.40M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
11.00 | 205.55M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
4.11 | 157.18M | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-04-16 | 다운그레이드 | Dawson James | Buy → Neutral |
Biocardia Inc 주식(BCDA)의 최신 뉴스
First subject enrolled in BioCardia’s Phase III heart failure therapy trial - Yahoo
Form 8-KCurrent report - ADVFN
BioCardia Advances Cardiac Cell Therapy With Start Of Phase 3 CardiAMP HF II Trial - Nasdaq
BioCardia (BCDA) Moves Forward With Phase III CardiAMP HF II Trial | BCDA Stock News - GuruFocus
BioCardia Enrolls First Patient in Phase III Trial - TipRanks
BioCardia's Revolutionary Cell Therapy Enters Final Testing Phase for Heart Failure TreatmentKey Trial Details - Stock Titan
BioCardia (BCDA) Gains Attention Amid Surge in Search Activity | - GuruFocus
Biocardia CFO David McClung buys $24,999 in company stock By Investing.com - Investing.com Nigeria
Biocardia CFO David McClung buys $24,999 in company stock - Investing.com
BioCardia Executives Increase Their Stakes in the Company - TradingView
Biocardia CEO Peter Altman acquires $1,488 in stock - MSN
Beating Heart Patch Market Detailed In New Research Report 2025 | - openPR.com
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results - ADVFN
Biocardia CEO Peter Altman buys $214 in company stock By Investing.com - Investing.com South Africa
Biocardia CEO Peter Altman buys $214 in company stock - Investing.com Australia
DSMB recommends continuation of BioCardia’s cell therapy trial for heart failure - Yahoo
BioCardia’s CardiALLO-HF trial receives DSMB nod to proceed By Investing.com - Investing.com South Africa
BioCardia (BCDA) Receives Positive DSMB Recommendation for Cardi - GuruFocus
Biocardia Announces Positive Dsmb Review Of Cardiallo Allogeneic Cell Therapy For Heart Failure Phase 1/2 Clinical Trial - marketscreener.com
BioCardia’s CardiALLO Trial Advances After Safety Review - TipRanks
BioCardia’s CardiALLO-HF trial receives DSMB nod to proceed - Investing.com
BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic - GuruFocus
BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial - The Manila Times
Major Safety Milestone: Revolutionary Heart Failure Cell Therapy Advances to Next Phase - Stock Titan
Biocardia CEO Altman purchases shares worth $1,206 - Investing.com Australia
Biocardia CEO Altman purchases shares worth $1,206 By Investing.com - Investing.com India
Emory begins enrolment for BioCardia’s trial of ischemic heart failure therapy - Yahoo Finance
BioCardia (BCDA) Advances Phase III CardiAMP HF II Trial with Em - GuruFocus
BioCardia Initiates Patient Enrollment at Emory University Schoo - GuruFocus
Emory University joins phase III heart failure trial By Investing.com - Investing.com South Africa
BioCardia Says Emory University Enrolling Heart Patients for CardiAMP HF II Trial - marketscreener.com
Emory University joins phase III heart failure trial - Investing.com Australia
BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study - The Manila Times
Biocardia Initiates Patient Enrollment At Emory University School Of Medicine - MarketScreener
BioCardia CEO Peter Altman purchases $980 in company stock By Investing.com - Investing.com South Africa
BioCardia CEO Peter Altman purchases $980 in company stock - Investing.com
BioCardia completes enrollment for heart therapy trial - MSN
Biocardia CEO Peter Altman acquires $1,632 in company shares By Investing.com - Investing.com South Africa
Biocardia CEO Peter Altman acquires $1,632 in company shares - Investing.com Australia
Biocardia CEO Peter Altman buys $2,435 in company stock By Investing.com - Investing.com South Africa
Biocardia Inc (BCDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):